PF-00299804: Phase II data

An international Phase II trial in 188 patients who had failed 1 or 2 prior chemotherapy regimens showed that 45 mg once-daily PF-00299804 met the primary endpoint of significantly increasing median PFS vs. 150 mg once-daily Tarceva erlotinib (12.4 vs. 8.3 weeks, p=0.03). In patients with wild-type K-Ras NSCLC (N=117), PF-00299804 also significantly increased median PFS vs. Tarceva (16.6 vs. 8.4 weeks, p=0.004). Additionally, PF-002998804 produced significantly greater objective response and clinical benefit rates vs. Tarceva (17% and 29.8%, respectively, vs. 6.4% and 14.9%; p=0.04 and p=0.02, respectively). Pfizer also said the compound improved various patient reported outcomes vs. Tarceva on the 30-item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core questionnaire (EORTC QLQ-C30) and its lung cancer module (LC13). Data were presented at the European Society for Medical Oncology meeting in Milan. ...